Prognostic significance of flow‐cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP‐AML 2002/01 study protocol

Summary In children with acute myeloid leukaemia (AML), assessment of initial treatment response is an essential prognostic factor; methods more sensitive than morphology are still under evaluation. We report on the measurement of minimal residual disease (MRD), by multicolour flow‐cytometry in one...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2017-04, Vol.177 (1), p.116-126
Main Authors: Buldini, Barbara, Rizzati, Frida, Masetti, Riccardo, Fagioli, Franca, Menna, Giuseppe, Micalizzi, Concetta, Putti, Maria Caterina, Rizzari, Carmelo, Santoro, Nicola, Zecca, Marco, Disarò, Silvia, Rondelli, Roberto, Merli, Pietro, Pigazzi, Martina, Pession, Andrea, Locatelli, Franco, Basso, Giuseppe
Format: Article
Language:English
Subjects:
Acute myeloid leukaemia
Acute myeloid leukemia
Adolescent
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Child
Child, Preschool
Children
Cytometry
Evaluation
Female
Flow Cytometry
Follow-Up Studies
Hematology
Humans
Immunophenotyping
Induction therapy
Infant
Infant, Newborn
Leukemia
Leukemia, Myeloid, Acute - diagnosis
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - mortality
Male
Minimal residual disease
Multivariate Analysis
Neoplasm, Residual - diagnosis
Paediatric
Risk group
Prognosis
Remission
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary In children with acute myeloid leukaemia (AML), assessment of initial treatment response is an essential prognostic factor; methods more sensitive than morphology are still under evaluation. We report on the measurement of minimal residual disease (MRD), by multicolour flow‐cytometry in one centralized laboratory, in 142 children with newly diagnosed AML enrolled in the Associazione Italiana di EmatoOncologia Pediatrica‐AML 2002/01 trial. At the end of the first induction course, MRD was 1% in 51 patients. The 8‐year disease‐free survival (DFS) of 125 children in morphological complete remission and with MRD
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.14523